VISX TO HIRE INDEPENDENT FIRM FOR REVIEW OF CLINICAL TRIAL SITES
This article was originally published in The Gray Sheet
Executive Summary
VISX TO HIRE INDEPENDENT FIRM FOR REVIEW OF CLINICAL TRIAL SITES in response to "concerns" expressed in FD-483 inspectional observation reports sent by FDA to two of the company's clinical investigative sites, the company said in a Sept. 7 teleconference. The review is voluntary and designed "to assure that ongoing clinical investigations are being conducted in compliance with regulatory requirements," the company said.
You may also be interested in...
EU Experts Want One-Stop-Shop EU Governance That Mimics Best Of Other Jurisdictions
It may be blue sky thinking to surmise how a new EU medtech regulatory governance structure could evolve. But with change on the horizon, experts see exciting opportunities.
How Ochre Bio Bagged Boehringer For Its RNA-Based Regenerative MASH Therapies
UK-based Ochre Bio has signed its first major deal with Boehringer Ingelheim. Scrip talked to its co-founder and CEO, Jack O’Meara, about its human tissue-based drug discovery platform, its resulting RNA platform for liver disease and how the fledgling drug company's early work mirrored that seen in diagnostics.
IGI Bets On Trispecific Antibody To Make Inroads Into Big Pharma Myeloma Turf
Ichnos Glenmark Innovation’s president and CEO talks to Scrip about the promising activity profile of the alliance’s early stage trispecific antibody versus Janssen’s teclistamab and also maintains that the setback for Gilead’s magrolimab hasn’t eclipsed prospects for its bispecific antibody.